The views in the linked paper represent a perspective from the Psychopharmacology Committee at GAP. The more provocative views expressed below are mine. What do YOU think this means for the system of psychiatric care that we have created (or has been created for us by the businesses that shape medicine)?
Ask a psychiatrist whether they prescribe according to the evidence and the answer will almost certainly be yes. Ask what that means, and the reply usually focuses on evidence-based matching of medications with defined DSM categories. In this month's American Journal of Psychiatry, The Psychopharmacology Committee of the Group for the Advancement of Psychiatry argues that optimal prescribing requires attention to all of our evidence bases, particularly those pertaining to the prescribing relationship.
That literature is more substantial than many of us were taught. Placebo effects, which produce real and often lasting biomedical changes, contribute at least as much to psychiatric pharmacotherapy outcomes as the medications themselves. In the NIMH TDCRP Study, alliance effects were equivalent in antidepressant pharmacotherapy and psychotherapy, accounting for more outcome variance than the purported active treatment. Meta-analytic data suggests that the effect size of the pharmacotherapeutic alliance (0.3) is on par with the effect size of our most prescribed medications.
The pharmacotherapeutic alliance offers a modifiable and evidence-based point of intervention to optimize treatment benefits. These effects may be particularly potent in psychiatry, where a majority of patients have histories of early adversity that may have undermined trust in caregiving. Meta-analytic data shows a nearly 1-point drop in the HAM-D with every additional appointment in the initiation phase of antidepressant treatment… a potent relational effect that is essentially ignored in clinical practice where patients are often seen less than monthly. Clinician warmth also reduces side-effects, improves follow-up, and corrects for the relational cost of briefer visits. Attending to patient preferences for treatment when weighting psychotherapy vs pharmacotherapy for depression can potentially boost treatment response 6-fold. Engaging with the patient rather than the EMR can triple the likelihood of the patient returning for a follow-up visit after intake. Countless other data on the effective prescribing process suggest, as did Michael Balint in his seminal 1957 text, that our most potent drug is the one called… “doctor.”
Not even counting vast private industry funding, over 6 billion dollars in federal funding goes into psychiatric research every year, which, as former NIMH director Tom Insel noted, noted, “has barely moved the needle” on psychiatric outcomes. Someday, we can hope that there will be big payoffs, but, in the meantime, countless patient suffer with recalcitrant mental illness. Given RDOC criteria, almost all of this funding focuses on neurobiological mechanisms rather than psychosocial aspects of psychiatric care. Given the substantial impacts of psychosocial factors on pharmacologic treatment outcomes, it seems likely that alliance research and dissemination of these findings could substantially improve psychiatric outcomes, could do it next year, and could do it at a fraction of the cost of the development of novel biomedical approaches.
In a culture and environment that overvalues medications and undervalues the power of the psychiatrist-patient relationship, the whole field has moved towards brief visits, often monthly or less. Strikingly, there is essentially no research on how this shift has impacted treatment outcomes or contributes to the problem of psychiatric treatment-resistance. When we do consider how much non-pharmacologic factors contribute to treatment outcomes, it raises serious questions about whether we have created a system of care delivery that is costing our patients more than we know.
Given that psychosocial factors often shape treatment outcomes as much as (or more than) the medications themselves, it is reasonable to ask whether a psychiatrist ignoring these evidence bases is really practicing evidence-based psychiatry. The potency of the pharmacotherapeutic alliance and other psychosocial factors shaping pharmacotherapy outcomes suggests that alliance-enhancing interventions should have better representation in our research agenda, our treatment algorithms, and our residency training. It could even be argued that, if half of pharmacotherapy outcome is shaped by nonpharmacologic factors, many of which are modifiable, should a commensurate amount of psychopharmacology training in residency focus not on what to prescribe, but, rather, the evidence addressing how to prescribe?
This is a crucial issue for our patients. It is also an existential issue for psychiatry. If we continue to neglect the impact of the doctor-patient relationship in shaping positive outcomes and treat psychiatry as if competence boils down simply to algorithmic matching of diagnoses and symptoms, our corporate overlords will soon succeed in their efforts to replace us with prescribing bots, and it will take a generation of patient suffering before we realize the disastrous folly of our biomedical reductionism. Psychiatry as a human endeavor cannot survive unless we recognize that our traditional expertise in the doctor-patient relationship is not a relic of a psychodynamic past but is essential to the effective treatment of our most troubled patients.